Active Ingredient(s): Abarelix
FDA Approved: * November 25, 2003
Pharm Company: * PRAECIS
Category: Cancer

Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[2][3] It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[2] and is now marketed... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.